General form of registration statement for all companies including face-amount certificate companies

STOCKHOLDERS DEFICIT (Details Narrative)

v3.24.1.1.u2
STOCKHOLDERS DEFICIT (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Sep. 01, 2023
Sep. 27, 2021
Jul. 30, 2021
Jan. 31, 2024
Mar. 31, 2024
Dec. 31, 2023
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Sep. 30, 2023
Sep. 30, 2022
Mar. 12, 2024
Jun. 18, 2013
Subsidiary, Sale of Stock [Line Items]                          
Common stock, par value         $ 0.001     $ 0.001   $ 0.001 $ 0.001    
Share-based compensation arrangement by share-based payment award, options, grants in period, gross               24,500 6,625    
Share-based compensation arrangement by share-based payment award, options, grants in period, weighted average exercise price               $ 8.00 $ 6.00    
Share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, minimum                   102.80% 86.80%    
Share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum                   103.40% 98.50%    
Share-based compensation arrangement by share-based payment award, fair value risk free interest rate, minimum                   3.80% 1.50%    
Share-based compensation arrangement by share-based payment award, fair value risk free interest rate, maximum                   4.00% 3.50%    
Share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate                   0.00% 0.00%    
Share-based compensation arrangement by share-based payment award, options, vested, number of shares         74,769         82,940      
Share based compensation               $ 25,909 $ 172,550 $ 249,555 $ 499,583    
Prefunded Warrants [Member]                          
Subsidiary, Sale of Stock [Line Items]                          
Issuance of common stock shares       300,073                  
Exercisable per share       $ 0.001               $ 0.001  
Common Stock [Member]                          
Subsidiary, Sale of Stock [Line Items]                          
Warrants and rights outstanding, term       5 years                  
Research and Development Expense [Member]                          
Subsidiary, Sale of Stock [Line Items]                          
Share-based payment arrangement, expense                   57,000 148,000    
General and Administrative Expense [Member]                          
Subsidiary, Sale of Stock [Line Items]                          
Share-based payment arrangement, expense                   $ 189,000 $ 311,000    
Minimum [Member]                          
Subsidiary, Sale of Stock [Line Items]                          
Share-based compensation arrangement by share-based payment award, fair value assumptions, expected term                   4 years 1 month 6 days 3 years 7 months 6 days    
Maximum [Member]                          
Subsidiary, Sale of Stock [Line Items]                          
Share-based compensation arrangement by share-based payment award, fair value assumptions, expected term                   5 years 9 months 18 days 5 years 9 months 18 days    
Employees, Directors and Consultants [Member]                          
Subsidiary, Sale of Stock [Line Items]                          
Share-based payment arrangement, expense                   $ 246,000 $ 459,000    
The 2013 Plan [Member]                          
Subsidiary, Sale of Stock [Line Items]                          
Share-based compensation arrangement by share-based payment award, options, grants in period, weighted average exercise price                   $ 8.02 $ 10.02    
Share-based compensation arrangement by share-based payment award, options, grants in period, aggregate grant date fair value                   $ 156,275 $ 47,609    
Share-based payment arrangement, nonvested award, cost not yet recognized, amount         $ 45,000     $ 45,000   $ 162,000      
Share-based payment arrangement, nonvested award, cost not yet recognized, period for recognition               1 year 4 months 2 days   1 year 9 months 18 days      
Granted shares                   0      
The 2013 Plan [Member] | Board of Directors and Management [Member]                          
Subsidiary, Sale of Stock [Line Items]                          
Share-based compensation arrangement by share-based payment award, options, grants in period, gross                   20,875 2,375    
The 2013 Plan [Member] | Consultants [Member]                          
Subsidiary, Sale of Stock [Line Items]                          
Share-based compensation arrangement by share-based payment award, options, grants in period, gross                   3,625 4,250    
2013 Stock Incentive Plan [Member]                          
Subsidiary, Sale of Stock [Line Items]                          
Issuance of common stock shares 455,169             0          
Granted shares                         185,571
Series G and Series H Warrants [Member]                          
Subsidiary, Sale of Stock [Line Items]                          
Shares issued from exchange of warrants                   12,019      
Conversion of Series One Convertible Notes Into Common Stock [Member]                          
Subsidiary, Sale of Stock [Line Items]                          
Debt conversion, converted instrument, shares issued                   59,912      
Second and Third Closing Notes [Member]                          
Subsidiary, Sale of Stock [Line Items]                          
Debt conversion, converted instrument, shares issued                   20,210      
Restricted Stock [Member]                          
Subsidiary, Sale of Stock [Line Items]                          
Stock issued during period, shares, restricted stock award, gross                   250      
Restricted Stock [Member] | Share-Based Payment Arrangement, Employee [Member] | Share-Based Payment Arrangement, Tranche One [Member]                          
Subsidiary, Sale of Stock [Line Items]                          
Share-based compensation arrangement by share-based payment award, options, vested, number of shares     250                    
Restricted Stock [Member] | The 2013 Plan [Member] | Share-Based Payment Arrangement, Employee [Member]                          
Subsidiary, Sale of Stock [Line Items]                          
Share-based compensation arrangement by share-based payment award, non-option equity instruments, granted     750                    
Restricted Stock [Member] | The 2013 Plan [Member] | Consultants [Member]                          
Subsidiary, Sale of Stock [Line Items]                          
Share-based compensation arrangement by share-based payment award, non-option equity instruments, granted   1,500                      
Share-Based Payment Arrangement, Option [Member] | The 2013 Plan [Member]                          
Subsidiary, Sale of Stock [Line Items]                          
Share-based compensation arrangement by share-based payment award, award vesting period                   36 months 36 months    
Share-Based Payment Arrangement, Option [Member] | The 2013 Plan [Member] | Board of Directors and Management [Member]                          
Subsidiary, Sale of Stock [Line Items]                          
Share-based compensation arrangement by share-based payment award, expiration period                   10 years 10 years    
Share-Based Payment Arrangement, Option [Member] | The 2013 Plan [Member] | Consultants [Member]                          
Subsidiary, Sale of Stock [Line Items]                          
Share-based compensation arrangement by share-based payment award, award vesting period                   12 months 12 months    
Share-based compensation arrangement by share-based payment award, expiration period                   5 years 5 years    
Restricted Shares [Member]                          
Subsidiary, Sale of Stock [Line Items]                          
Share-based payment arrangement, expense         $ 0   $ 1,000 $ 0 $ 3,000 $ 3,000 $ 40,000    
All Stock Issuances [Member]                          
Subsidiary, Sale of Stock [Line Items]                          
Issuance of common stock shares       300,000           3,436,712      
Financing Activities With Accredited Investors [Member]                          
Subsidiary, Sale of Stock [Line Items]                          
Issuance of common stock shares                   3,344,321      
Proceeds from issuance or sale of equity                   $ 2,209,839